Stevens-Johnson syndrome induced by teriprizumab
10.3760/cma.j.cn114015-20210925-01017
- VernacularTitle:特瑞普利单抗致Stevens-Johnson综合征
- Author:
Chao LI
1
;
Ya CHEN
;
Guiqin PENG
;
Hao BAI
;
Xiangyu LAI
;
Wanyi CHEN
Author Information
1. 重庆大学附属肿瘤医院药学部，重庆 400030
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Stevens-Johnson syndrome;
Teriprizumab
- From:
Adverse Drug Reactions Journal
2022;24(5):273-275
- CountryChina
- Language:Chinese
-
Abstract:
A 56-year-old male patient with lymphoma received anti-tumor treatments with treprizumab (intravenous infusion of 240 mg once every 21 days) combined with rituximab, gemcitabine, and oxaliplatin. On day 5 after the first treatment of treprizumab, the patient developed rash all over the body and a large area of erythema on the trunk and limbs, accompanied by pruritus and pain, and the exfoliation area of the whole body was more than 30%. Laboratory tests showed white blood cell count 12.4×10 9/L, neutrophil count 11.5×10 9/L, erythrocyte sedimentation rate 162 mm/1 h, C-reactive protein 74 mg/L, and procalcitonin 1.09 μg/L. The patient had received antineoplastic therapy with rituximab, gemcitabine, and oxaliplatin and no skin reaction occurred. Stevens-Johnson syndrome induced by treprizumab was considered. Protective isolation care and symptomatic treatments such as glucocorticoid, immunoglobulin, and anti-infection were given. After 23 days of treatments, the patient was improved, and the skin ulceration area decreased to 10%. After 31 days of treatments, regenerated skin appeared under most of the ulcerated skin, and laboratory tests showed erythrocyte sedimentation rate 46 mm/1 h, C-reactive protein 15 mg/L, and procalcitonin 0.04 μg/L.
